As summarized on the slide, numerous novel pharmacological treatment approaches are under clinical development for generalized anxiety disorder, social anxiety disorder, and specific phobias.1-8
References:
1. Sartori SB, Singewald N. Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders. Pharmacol Ther 2019; 204: 107402.
2. Sah A, Singewald N. The (neuro)inflammatory system in anxiety disorders and PTSD: Potential treatment targets. Pharmacol Ther 2025; 269: 108825.
3. Domschke K, Singewald N. Emerging pharmacological treatments for anxiety disorders. [citation needed]
4. Hou R, Baldwin DS. A neuroimmunological perspective on anxiety disorders. Hum Psychopharmacol 2012; 27 (1): 6–14.
5. Vullo S, Kellenberger S. A molecular view of the function and pharmacology of acid-sensing ion channels. Pharmacol Res 2020; 154: 104166.
6. Baldwin DS, Hou R, Gordon R, et al. Pharmacotherapy in generalized anxiety disorder: novel experimental medicine models and emerging drug targets. CNS Drugs 2017; 31 (4): 307–317.
7. Salvadore G, Bonaventure P, Shekhar A, et al. Translational evaluation of novel selective orexin-1 receptor antagonist JNJ-61393215 in an experimental model for panic in rodents and humans. Transl Psychiatry 2020; 10 (1): 308.
8. Chen X, van Gerven J, Cohen A, Jacobs G. Human pharmacology of positive GABA-A subtype-selective receptor modulators for the treatment of anxiety. Acta Pharmacol Sin 2019; 40 (5): 571–582.
9. Simen A, Whitlock M, Qiu R, et al. An 8-week, randomized, phase 2, double-blind, sequential parallel-group comparison of two dose levels of the GABAA positive allosteric modulator PF-06372865 compared with placebo as an adjunctive treatment in outpatients with inadequate response to standard of care for generalized anxiety disorder. J Clin Psychopharmacol 2019; 39 (1): 20‒27.
10. Black N, Stockings E, Campbell G, et al. Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. Lancet Psychiatry 2019; 6 (12): 995–1010.
11. Chagraoui J, Girard S, Spinella JF, et al. UM171 preserves epigenetic marks that are reduced in ex vivo culture of human HSCs via potentiation of the CLR3-KBTBD4 complex. Cell Stem Cell 2021; 28 (1): 48–62.
12. Weston NM, Gibbs D, Bird CIV, et al. Historic psychedelic drug trials and the treatment of anxiety disorders. Depress Anxiety 2020; 37 (12): 1261–1279.
